Administration of low doses of tumor necrosis factor-alpha protects rat liver from ischaemic damage and reperfusion injury

Journal of Physiology and Pharmacology

Volumn 61, Issue 3, 2010, Pages 273-278

  Helewski, K J ^a   Kowalczyk Ziomek, G I ^a   Czecior, E ^b   Swietochowska, E ^a   Wielkoszynski, T ^a   Czuba, Z P ^a   Szliszka, E ^a   Krol, W ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b ENT Department of Medical University of Silesia   (Poland)

Author keywords

Alanine aminotransferase; Ischaemia reperfusion injury; Liver; Malondialdehyde; Myeloperoxidase; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; MALONALDEHYDE; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; PEROXIDASE; PROTECTIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; LIPID PEROXIDATION; LIVER ISCHEMIA; LIVER PROTECTION; LOW DRUG DOSE; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY; ANIMAL; BLOOD; DRUG EFFECTS; LIVER; LIVER DISEASES; METABOLISM; PATHOLOGY; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; LIVER; LIVER DISEASES; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PEROXIDASE; PROTECTIVE AGENTS; RATS; RATS, WISTAR; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957040183     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000; 32: 169-173.
2. Jaeschke H. Molecular mechanisms of hepatic ischemiareperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284: G15-G26.
3. Menger MD, Vollmar B. Pathomechanisms of ischemiareperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? Transplant Proc 2007; 39: 485-488.
4. Serafin A, Fernandez-Zabalegui L, Prats N, Wu ZY, Rosello-Catafau J, Peralta C. Ischemic preconditioning: tolerance to hepatic ischemia-reperfusion injury. Histol Histopathol 2004; 19: 281-289.
5. Jaeschke H. Role of reactive oxygen species in hepatic ischemia-reperfusion injury and preconditioning. J Invest Surg 2003; 16: 127-140.
6. Okaya T, Lentsch AB. Cytokine cascade and the hepatic inflammatory response to ischemia and reperfusion. J Invest Surg 2003; 16: 141-147.
7. Zapolska-Downar D, Maruszewicz M. Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor-k B (NF-k) activation. J Physiol Pharmacol 2009; 60: 123-131.
8. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 2003; 125: 1246-1257.
9. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemiareperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1083-G1088.
10. Helewski K, Kowalczyk-Ziomek G, Konecki J. Udzial neutrofili w uszkodzeniu watroby na skutek niedokrwienia I reperfuzji. Wiad Lek 2007; 60: 47-52.
11. Martinez-Mier G, Toledo-Pereyra LH, Mc Duffie JE, Warner RL, Ward PA. Neutrophil depletion and chemokine response after liver ischemia and reperfusion. J Invest Surg 2001; 14: 99-107.
12. Kim YI, Song KE, Ryeon HK, et al. Enhanced inflammatory cytokine production at ischemia/reperfusion in human liver resection. Hepatogastroenterology 2002; 49: 1077-1082.
13. Ben-Ari Z, Hochhauser E, Burstein I, et al. Role of anti-tumor necrosis factor-alpha in ischemia/reperfusion injury in isolated rat liver in a blood-free environment. Transplantation 2002; 73: 1875-1880.
14. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-a-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583-G589.
15. Lentsch AB, Yoshidome H, Kato A, et al. Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 1999; 30: 1448-1458.
16. Scales WE, Campbell DA, Green ME, Remick DG. Hepatic ischemia/reperfusion injury: importance of oxidant/tumor necrosis factor interactions. Am J Physiol Gastrointest Liver Physiol 1994; 267: G1122-G1127.
17. Yang YL, Li JP, Xu XP, Dou KF, Yue SQ, Li KZ. Protective effects of tumor necrosis factor alpha antibody and ulinastatin on liver ischemic reperfusion in rats. World J Gastroenterol 2004; 10: 3161-3164.
18. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85: 1936-1943.
19. Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-936.
20. Teoh N, Leclercq I, Pena AD, Farrell G. Low-dose TNFalpha protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning. Hepatology 2003; 37: 118-128.
21. Teoh N, Field J, Sutton J, Farrell G. Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-alpha gene knockout mice. Hepatology 2004; 39: 412-421.
22. Asakawa H, Jeppsson B, Mack P, Hultberg B, Hagerstrand I, Bengmark S. Acute ischemic liver failure in the rat: a reproducible model not requiring portal decompression. Eur Surg Res 1989; 21: 42-48.
23. Wroblewski F, La Due JS. Serum glutamic pyruvic transaminase in cardiac and hepatic disease. Proc Soc Exp Biol Med 1956; 91: 569-571.
24. Henry RJ, Chiamori N, Golub OJ, Berkman S. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Am J Clin Pathol 1960; 34: 381-398.
25. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978; 24: 58-73.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
27. Scales WE, Campbell DA, Green ME, Remick DG. Hepatic ischemia/reperfusion injury: importance of oxidant/tumor necrosis factor interactions. Am J Physiol Gastrointest Liver Physiol 1994; 267: G1122-G1127.
28. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003; 18: 891-902.
29. Peralta C, Perales JC, Bartrons R, et al. The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion. Am J Pathol 2002; 160: 2111-2122.
30. Colletti LM, Kunkel SL, Walz A, et al. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 1996; 23: 506-514.
31. Yuan GJ, Ma JC, Gong ZJ, Sun XM, Zheng SH, Li X. Modulation of liver oxidant-antioxidant system by ischemic preconditioning during ischemia/reperfusion injury in rats. World J Gastroenterol 2005; 11: 1825-1828.
32. Jiang Y, Gu XP, Qiu YD, et al. Ischemic preconditioning decreases C-X-C chemokine expression and neutrophil accumulation early after liver transplantation in rats. World J Gastroenterol 2003; 9: 2025-2029.
33. Glanemann M, Strenziok R, Kuntze R, et al. Ischemic preconditioning and methylprednisolone both equally reduce hepatic ischemia/reperfusion injury. Surgery 2004; 135: 203-214.
34. Chouker A, Martignoni A, Schauer R, et al. Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils. Arch Surg 2005; 140: 129-136.
35. Hasegawa T, Malle E, Farhood A, Jaeschke H. Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning. Am J Physiol Gastrointest Liver Physiol 2005; 289: G760-G767.
36. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9: 515-540.
37. Jung SE, Yun IJ, Youn YK, et al. Effect of protease inhibitor on ischemia-reperfusion injury to rat liver. World J Surg 1999; 23: 1027-1031.
38. Rhee JE, Jung SE, Shin SD, et al. The effects of antioxidants and nitric oxide modulators on hepatic ischemic-reperfusion injury in rats. J Korean Med Sci 2002; 17: 502-506.
39. Mathews WR, Guido DM, Fisher MA, Jaeschke H. Lipid peroxidation as molecular mechanism of liver cell injury during reperfusion after ischemia. Free Radic Biol Med 1994; 16: 763-770.
40. Kaplan N, Yagmurdur H, Kilinc K, Baltaci B, Tezel S. The protective effects of intravenous anesthetics and verapamil in gut ischemia/reperfusion-induced liver injury. Anesth Analg 2007; 105: 1371-1378.
41. Giakoustidis D, Kontos N, Iliadis S, et al. Severe total hepatic ischemia and reperfusion: relationship between very high alpha-tocopherol uptake and lipid peroxidation. Free Radic Res 2001; 35: 103-109.
42. Kukan M. Emerging roles of proteasomes in ischemiareperfusion injury of organs. J Physiol Pharmacol 2004; 55: 3-15.
43. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophildependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998; 10: 182-191.
44. Hendryk S, Czuba ZP, Jedrzejowska-Szypulka H, et al. Influence of 5-aminoisoquinolin -1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischaemia and after reperfusion. J Physiol Pharmacol 2008; 59: 811-822.
45. Su JF, Guo CJ, Wei JY, Yang JJ, Jiang YG, Li YF. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomed Environ Sci 2003; 16: 1-8.